Lilly Adds $20M To Investment In Chinese Drugmaker

Law360, Los Angeles (June 12, 2012, 6:57 PM EDT) -- Eli Lilly & Co. plans to increase its investment in Chinese generic and specialty pharmaceutical manufacturer Novast Laboratories Ltd. by $20 million, the Indianapolis-based pharmaceutical giant announced Tuesday, saying the equity investment will help it build a portfolio of Lilly-branded generics in China.

“In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline, as well as select Lilly-branded generic medicines that meet our quality standards,” Lilly’s president of emerging markets Jacques Tapiero said Tuesday. “The additional manufacturing capabilities...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.